3420 related items for PubMed ID: 16750460
1. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ.
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[Abstract] [Full Text] [Related]
2. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ, Figgitt DP.
CNS Drugs; 2004 Apr; 18(6):379-96. PubMed ID: 15089110
[Abstract] [Full Text] [Related]
3. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
van de Wyngaert FA, Beguin C, D'Hooghe MB, Dooms G, Lissoir F, Carton H, Sindic CJ.
Acta Neurol Belg; 2001 Dec; 101(4):210-6. PubMed ID: 11851027
[Abstract] [Full Text] [Related]
4. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G, Filippi M, Wolinsky JS.
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[Abstract] [Full Text] [Related]
5. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B.
Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
[Abstract] [Full Text] [Related]
6. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung HP, MIMS Study Group.
Neurology; 2005 Sep 13; 65(5):690-5. PubMed ID: 16157900
[Abstract] [Full Text] [Related]
7. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
[Abstract] [Full Text] [Related]
8. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
Ostberg A, Pittas F, Taylor B.
Intern Med J; 2005 Jul 04; 35(7):382-7. PubMed ID: 15958106
[Abstract] [Full Text] [Related]
9. [Mitoxantrone].
Pericot I, Montalban X.
Neurologia; 2003 Jul 04; 18(6):318-23. PubMed ID: 12838451
[Abstract] [Full Text] [Related]
10. Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G.
Cochrane Database Syst Rev; 2013 May 31; (5):CD002127. PubMed ID: 23728638
[Abstract] [Full Text] [Related]
11. Rationale for the use of mitoxantrone in multiple sclerosis.
Edan G, Morrissey S, Le Page E.
J Neurol Sci; 2004 Aug 15; 223(1):35-9. PubMed ID: 15261558
[Abstract] [Full Text] [Related]
12. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
De Stefano N, Filippi M, Hawkins C, 9011 study group.
J Neurol Sci; 2008 Mar 15; 266(1-2):44-50. PubMed ID: 17897678
[Abstract] [Full Text] [Related]
13. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP, Rovaris M, Comi G, Filippi M.
Neurology; 2009 Nov 10; 73(19):1538-42. PubMed ID: 19794123
[Abstract] [Full Text] [Related]
14. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Amato MP.
J Neurol Sci; 2008 Mar 15; 266(1-2):25-30. PubMed ID: 17870094
[Abstract] [Full Text] [Related]
15. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR, Panitch HS.
Clin Ther; 2007 Sep 15; 29(9):2031-48. PubMed ID: 18035202
[Abstract] [Full Text] [Related]
16. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
Clin Ther; 2008 Jun 15; 30(6):1102-12. PubMed ID: 18640466
[Abstract] [Full Text] [Related]
17. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
[Abstract] [Full Text] [Related]
18. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
Arch Neurol; 2008 Feb 10; 65(2):199-204. PubMed ID: 18071030
[Abstract] [Full Text] [Related]
19. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
Calabrese M, Rocca MA, Atzori M, Mattisi I, Favaretto A, Perini P, Gallo P, Filippi M.
Ann Neurol; 2010 Mar 10; 67(3):376-83. PubMed ID: 20373349
[Abstract] [Full Text] [Related]
20. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H, ACT Investigators.
Mult Scler; 2008 Apr 10; 14(3):370-82. PubMed ID: 18208877
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
